Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Ann Med. 2023;55(2):2282652. doi: 10.1080/07853890.2023.2282652. Epub 2023 Nov 27.
Second primary malignancies (SPMs) account for an increasing proportion of human malignancies. We estimated the incidence, risk factors and outcomes in lymphoma survivors with SPMs.
Patients diagnosed with SPMs after primary lymphoma from 2010 to 2021 were included in this study. The incidence, mortality and clinical characteristics of SPMs in our center and Surveillance, Epidemiology, and End Results database were delineated and analyzed. Standardized incidence ratio quantified second cancer risk.
A total of 2912 patients of lymphoma were included, 63 cases of SPM met the inclusion criteria, with the prevalence of SPMs after lymphoma was 2.16%. The male-to-female ratio of 2.32:1. The majority of these patients were older (≥60 years old, 61.90%) and previously treated with chemotherapy (68.25%). The common types among SPMs were digestive system tumors (42.86%), respiratory system tumors (20.63%) and urinary system tumors (12.70%). Additionally, cancer risks were significantly elevated after specific lymphoma though calculating the expected incidence. In terms of mortality, the diagnosis of SPMs was significantly associated with an increased risk of death over time. Moreover, although the outcome was favorable in some SPM subtypes (thyroid and breast cancer), other SPMs such as stomach and lung tumors had a dismal prognosis.
With the improvement of medical standards, the survival of lymphoma patients has been prolonged. However, the incidence of SPM is increasing, particularly among men and older lymphoma survivors. Therefore, more attention should be invested in the SPM to further improve the prognosis of these patients.
第二原发恶性肿瘤(SPM)在人类恶性肿瘤中的比例不断增加。我们评估了淋巴瘤幸存者发生 SPM 的发病率、风险因素和结局。
本研究纳入了 2010 年至 2021 年期间原发性淋巴瘤后诊断为 SPM 的患者。描述和分析了本中心和监测、流行病学和最终结果数据库中 SPM 的发病率、死亡率和临床特征。标准化发病比量化了第二癌症风险。
共纳入 2912 例淋巴瘤患者,63 例 SPM 符合纳入标准,淋巴瘤后 SPM 的患病率为 2.16%。男女比例为 2.32:1。这些患者大多数年龄较大(≥60 岁,61.90%)且先前接受过化疗(68.25%)。SPM 中常见的类型是消化系统肿瘤(42.86%)、呼吸系统肿瘤(20.63%)和泌尿系统肿瘤(12.70%)。此外,通过计算预期发病率,特定淋巴瘤后癌症风险显著升高。就死亡率而言,随着时间的推移,诊断 SPM 与死亡风险增加显著相关。此外,尽管某些 SPM 亚型(甲状腺癌和乳腺癌)的结局良好,但其他 SPM 如胃癌和肺癌的预后较差。
随着医疗标准的提高,淋巴瘤患者的生存率得到了延长。然而,SPM 的发病率正在增加,尤其是在男性和老年淋巴瘤幸存者中。因此,应该更加关注 SPM,以进一步改善这些患者的预后。